APTO Earnings Prediction
The chart below shows how APTO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, APTO sees a -4.07% change in stock price 10 days leading up to the earnings, and a +0.03% change 10 days following the report. On the earnings day itself, the stock moves by +2.84%. This data can give you a slight idea of what to expect for the next quarter's release.
APTO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-1.52
-6.17%
-13.64%
No Data Available
APTO Earnings Analysis
Aptose Biosciences Inc. Corporation (APTO.O) Earnings Conference Call
Positive
- The company successfully raised gross proceeds of $13.7 million in January 2024 through a public offering and a private placement, providing financial stability and resources for future operations.
- The additional capital raised through financing activities allowed Aptose Biosciences to fund planned operations, including research and development through August 2024.
- The gross proceeds from the public offering and private placement were approximately $13.7 million, contributing to the company's financial resources.
- The lead drug, Tuspetinib, demonstrated broad activity across AML populations with excellent safety profiles in single-agent trials, paving the way for potential frontline triplet combination therapies.
- Tuspetinib showcased an excellent safety profile and broad activity across AML populations in single-agent dose escalation studies, supporting its potential in combination therapies.
- The selection of the recommended Phase 2 dose for single-agent therapy and positive safety outcomes further reinforce Tuspetinib's suitability for combination therapies in frontline AML treatment.
- The planned Tuspetinib/Venetoclax/Azacitidine triplet pilot study in frontline newly diagnosed AML patients aims to establish a new standard of care, potentially exceeding a $1 billion market opportunity annually.
- The initiation of the pilot study in frontline AML patients aligns with market demands for more effective and less toxic frontline therapeutic options, showcasing market potential and significant patient impact.
- Expectations of initial findings by ASH 2024 and the potential support for registrational programs in 2025 highlight the strategic value and market opportunity for the Tuspetinib triplet therapy.
- Luxeptinib, another drug in Aptose Biosciences' portfolio, has demonstrated tumor shrinkage and activity in B-cell cancers and AML patients, with the development of a new G3 formulation showing promising outcomes.
- Luxeptinib's clinical data indicates activity in AML and B-cell cancer patients, with the new G3 formulation achieving desired plasma exposure benchmarks and better tolerability, setting the stage for focused clinical development programs.
- Explore potential collaborations to advance Luxeptinib in treating relapsed/refractory hematologic malignancies, expanding treatment options for high unmet medical needs patient populations.
Negative
- The company recorded a net loss of approximately $51.2 million in 2023, an increase from $41.8 million in 2022, leading to a loss per share of $7.58.
- Aptose Biosciences had no revenues in 2023, indicating a lack of income generation from its operations.
- The CFO mentioned a decrease in cash and investments by $27.7 million in 2023, leading to approximately $9.3 million in cash, which may raise concerns about the company's financial health.
- Aptose received a deficiency letter from NASDAQ regarding violation of listing rules due to a private placement, potentially affecting the company's stock listing.
